Dulaglutide
Sources
registry, as of 2026-09-15Stale
https://clinicaltrials.gov/study/NCT07820111
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial. Overall status COMPLETED. Phases PHASE3. Lead sponsor Zagazig University. Enrollment 159. Conditions Obese Diabetics; Obese Non Diabetic. titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Abstract : Background: This study that highlights the different effects of most used three GLP-RA Dulaglutide, Semaglutide, Tirazepetide among diabetic
ClinicalTrials.gov NCT07820111 protocol and results modules
registry, as of 2026-09-22Stale
https://clinicaltrials.gov/study/NCT07834398
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Zagazig University. Enrollment 150. Conditions Non-diabetec Obesity; Obesity (Disorder). This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess change
ClinicalTrials.gov NCT07834398 protocol and results modules
registry, as of 2022-11-07Stale
https://clinicaltrials.gov/study/NCT04189848
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc. Overall status COMPLETED. Phases PHASE4. Lead sponsor Novo Nordisk A/S. Enrollment 104. Conditions Healthy Volunteers; Diabetes Mellitus, Type 2; Overweight; Obesity. This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will
ClinicalTrials.gov NCT04189848 protocol and results modules
registry, as of 2024-05-30Stale
https://clinicaltrials.gov/study/NCT03743025
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients. Overall status TERMINATED. Phases PHASE4. Lead sponsor Emory University. Enrollment 28. Conditions Stress Hyperglycemia. This study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period. deaths Dulaglutide 0 nausea Dulaglutide 2 deaths Placebo 0 nausea Placebo 1
ClinicalTrials.gov NCT03743025 protocol and results modules
registry, as of 2024-12-05Stale
https://clinicaltrials.gov/study/NCT04387201
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response. Overall status COMPLETED. Phases PHASE4. Lead sponsor The University of Texas Health Science Center, Houston. Enrollment 23. Conditions Glucose Intolerance; Overweight and Obesity; Drug Effect; Adiposity. This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborat deaths Cyanocobalamin 0 deaths Dulaglutide 0
ClinicalTrials.gov NCT04387201 protocol and results modules
registry, as of 2025-10-15Stale
https://clinicaltrials.gov/study/NCT07096063
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk. Overall status COMPLETED. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 887132. Conditions Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk. Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how
ClinicalTrials.gov NCT07096063 protocol and results modules
registry, as of 2026-07-09Stale
https://clinicaltrials.gov/study/NCT07619495
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk. Overall status COMPLETED. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 120000. Conditions Type 2 Diabetes Mellitus; Obesity; Overweight. Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how
ClinicalTrials.gov NCT07619495 protocol and results modules
registry, as of 2026-07-09Stale
https://clinicaltrials.gov/study/NCT07417618
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD). Overall status COMPLETED. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 60000. Conditions Type 2 Diabetes; Overweight; ASCVD. Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how
ClinicalTrials.gov NCT07417618 protocol and results modules
registry, as of 2022-03-14Stale
https://clinicaltrials.gov/study/NCT04829903
Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin. Overall status COMPLETED. Phases NA. Lead sponsor Corporacion Parc Tauli. Enrollment 116. Conditions Type 2 Diabetes Treated With Insulin; Obesity; Adolescent Obesity. To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents using metformin
ClinicalTrials.gov NCT04829903 protocol and results modules
registry, as of 2023-05-10Stale
https://clinicaltrials.gov/study/NCT04200625
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue. Overall status COMPLETED. Phases not stated. Lead sponsor University of Miami. Enrollment 80. Conditions Epicardial Fat. Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP
ClinicalTrials.gov NCT04200625 protocol and results modules
registry, as of 2024-03-26Stale
https://clinicaltrials.gov/study/NCT06331286
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity. Overall status UNKNOWN. Phases NA. Lead sponsor First Affiliated Hospital of Zhejiang University. Enrollment 60. Conditions Bipolar Disorder; Obesity; Cognition. The primary objective of this study is to investigate the effect of dulaglutide adjuvant treatment in patients with bipolar disorder with obesity, in addition to exploring the effect of GLP-1RA on cognition of bipolar disorder.
ClinicalTrials.gov NCT06331286 protocol and results modules